Aside from mental health applications, psychedelics are also known for their antiinflammatory effects. And now, a company called Eleusis has received data from a preclinical study that may pave the way for psychedelic medicines to treat antiinflammatory conditions.
The company’s researchers investigated 21 psychedelic compounds known to target the serotonin receptor 5-HT2A. Previous research conducted on mice showed that activation of this receptor has an antiinflammatory effect on tissues of the blood vessels and gut. In particular, it was shown to reduce inflammation in asthma patients.
Aware of their antiinflammatory potential, the researchers wanted to find a psychedelic that would not have the behavioral effects of most psychedelics. As such, they looked at how each of the drugs behaved in rats with allergic asthma. Although all drugs activated the 5-HT2A receptor, they differed in the ability to prevent airway constriction. Surprisingly, the researchers noted that LSD was ineffective.